

GC04 Rec'd PCT/PTO 0 8 JAN 2001

Docket No. J&J-1763

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Fist et al.

Serial No. : 09/600,500

Art Unit:

Filed : July 14, 2000

Examiner:

For : IMPROVED PRODUCTION OF RETICULINE



7
IDS
yv
4/17/01

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231 on

January 4, 2001
(Date of Deposit)

John W. Harbour
(Name of applicant, assignee, or Registered Representative)

(Signature)

January 4, 2001
(Date of Signature)

RECEIVED

MAR 12 2001

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with §1.97(e) is set forth below; or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$240.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

☐ Certification in Accordance with §1.97(e) is set forth below; or

☐ Please charge Deposit Account No. 10-0750/ - - - / the fee of \$240.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Certification in Accordance with §1.97(e) as set forth below and the fee of \$130.00 as set forth in §1.17(i)(1).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:

☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. , filed .


☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ The relevance of those listed references which are not in the English language is as follows:

☒ There are no listed references which are not in the English language.



Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/J&J1763/JWH. This form is submitted in triplicate.



Respectfully submitted,



John W. Harbour
Reg. No. 31365
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2169
DATED: January 4, 2001



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION  	Docket No.	Serial No.
	J&J-1763	09/600,500
	Applicant	
	Fist et al.	
Filing Date	Group Art Unit	
July 14, 2000		

U.S. PATENT DOCUMENTS

Exam'r Init.	Document No.	Date	Name	Class	Sub Class	File Date
-----------------	--------------	------	------	-------	--------------	-----------

FOREIGN PATENT DOCUMENTS

Exam'r Init.	Document No.	Date	Country	Class	Sub Class	Translate (select one) Yes No
-----------------	--------------	------	---------	-------	--------------	-------------------------------------

OTHER REFERENCES (include author, title, date, pertinent pages, etc.)

	Molecular characterization of berberine bridge enzyme genes from opium poppy. Pacchini, P.J.; Penzes, C.; Johnson, A.G.; Bull, D. Plant physiology, December 1996, Vol. 112, No. 4p. 1669-1677
	The Use of experimental mutagenesis in the breeding of the opium poppy Ivanova, R.M. Sov Genet, January 1972 (transl. March 1974) Vol. 8, No. 1, pp. 21-26
	The morphine content of third generation Papaver somniferum plants after a successive treatment with gamma rays and alkylating agents in the first and second generations Ghiorghita, G.I.; Gille, Elvira V.; Toth, Ecaterina T.; Sava, I.R. Rev. Roum, Biochim. (1983), 20(3), 161-8
	Study of some genetic factors leading to increased opium and morphine yield in opium poppy Singh, U.P. Adv. Biosci. (Oxford) (1989), 75 (Prog. Opioid Res.), 379-82.
	The influence of some successive mutagenic treatments on the capsules dimensions and the morphine content of Papaver somniferum L. Floria, F.; Gille, Elvira; Miricioiu, Ecaterina Rev. Roum. Biochim. (1986), 23(4), 285-92
	Some varieties of Papaver somniferum L. with changed morphinane alkaloid content Nyman, Ulf; Hall, Ove Hereditas (1976), 84(1), 69-76
	Selection for high thebaine/low morphine content (cpv. Morph: The) in Papaver somniferum L Nyman, Ulf Hereditas (1978), 89(1), 43-50
	Mutagenic effects of combined and single doses of gamma rays and EMS in opium poppy. Chauhan, S.P.; Patra, N.K. Plant breeding=Zeitschrift fur Pflanzenzuchtung, May 1993. Vol. 110, No. 4. P. 342-345
	Morphophysiology and genetics of induced mutants expressed in the M1 generation in opium poppies Patra, N.K.; Chauhan, S.P. The Journal of heredity, Sept/Oct 1990. Vol. 81, No. 5. P. 347-350
	The influence of the treatment with alkylating agents on Papaver somniferum L., in M1 Cytogenesis, mutation physiology, biochemistry. Floria, F.G.; Ghiorghita, G.I. Revue roumaine de biologie. Serie de biologie vegetale. July/Dec 1980 Vol. 25 No. 2. P 151-155
	Characterization and mechanism of the berberine bridge enzyme, a covalently flavinylated oxidase of benzophenanthridine alkaloid biosynthesis in plants. Kutchan, T.M.; Dittrich, H. The Journal of biological chemistry, October 13, 1995. Vol. 270, No. 41
	Enzymic formation of (R)-reticuline from 1,2-dehydroreticuline in the opium poppy plant De-Eknamkul, W.; Zenk, M.H. Tetrahedron Lett. (1990), 31(34), 4855-8
	Homogeneous 1,2-dehydroreticuline reductase from the opium poppy plant De-Eknamkul; Wanchai, Zenk, Meinhardt, H. Microb. Util. Renewable resour. (1991), Vol Date 1990, 7, 87-98

Examiner:	Date Considered
Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	